SC
VRTX icon

Savant Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Savant Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
3,856
+449
+13% +$209K 0.01% 458
2025
Q4 		$1.54M Buy
3,407
+481
+16% +$207K 0.01% 458
2025
Q3 		$1.15M Buy
2,926
+411
+16% +$172K 0.01% 535
2025
Q2 		$1.12M Buy
2,515
+327
+15% +$151K 0.01% 489
2025
Q1 		$1.06M Sell
2,188
-4,462
-67% -$2.08M 0.01% 458
2024
Q4 		$2.68M Sell
6,650
-383
-5% -$178K 0.02% 369
2024
Q3 		$3.27M Buy
7,033
+472
+7% +$227K 0.03% 304
2024
Q2 		$3.08M Buy
6,561
+3,127
+91% +$1.36M 0.03% 280
2024
Q1 		$1.44M Buy
3,434
+763
+29% +$323K 0.02% 441
2023
Q4 		$1.09M Buy
2,671
+624
+30% +$231K 0.01% 399
2023
Q3 		$712K Buy
2,047
+62
+3% +$21.7K 0.01% 461
2023
Q2 		$699K Buy
1,985
+820
+70% +$276K 0.01% 454
2023
Q1 		$367K Buy
1,165
+244
+26% +$73.2K 0.01% 540
2022
Q4 		$266K Buy
921
+142
+18% +$43.3K 0.01% 496
2022
Q3 		$226K Buy
779
+50
+7% +$14.4K 0.01% 485
2022
Q2 		$205K Buy
+729
New +$195K 0.01% 526
2016
Q1 		– Sell
-2,074
Closed -$261K – 242
2015
Q4 		$261K Buy
+2,074
New +$250K 0.08% 184

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Savant Capital's VRTX Position: Q1 2026 in Review

Savant Capital increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $209K and bringing the position to 3,856 shares worth $1.72M. The position accounts for 0.01% of the portfolio, ranked #458.

Savant Capital first reported a position in VRTX in Q4 2015 and has held it in 17 quarters since. The position peaked at $3.27M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Savant Capital held 3,856 shares of Vertex Pharmaceuticals worth $1.72M as of Q1 2026.
  • Savant Capital bought 449 Vertex Pharmaceuticals shares in Q1 2026, an estimated $209K.
  • Vertex Pharmaceuticals made up 0.01% of Savant Capital's portfolio in Q1 2026, its #458 holding.
  • Savant Capital first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 17 quarters since.
  • Savant Capital's Vertex Pharmaceuticals position peaked at $3.27M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Savant Capital's 13F filing for Q1 2026, filed 4 May 2026.